GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Notes Receivable

CERO (CERo Therapeutics Holdings) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Notes Receivable?

CERo Therapeutics Holdings's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


CERo Therapeutics Holdings Notes Receivable Historical Data

The historical data trend for CERo Therapeutics Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Notes Receivable Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CERo Therapeutics Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


CERo Therapeutics Holdings Notes Receivable Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, South San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

CERo Therapeutics Holdings Headlines